Medical therapy with tranexamic acid in autosomal dominant polycystic kidney disease patients with severe haematuria;Tratamiento con ácido tranexámico de la hematuria incoercible en la poliquistosis renal autosómica dominante

Nefrologia

Volumn 32, Issue 2, 2012, Pages 160-165

  Peces, Ramón ^a   Aguilar, Ana ^a   Vega, Cristina ^a   Cuesta, Emilio ^a   Peces, Carlos ^b   Selgas, Rafael ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b SESCAM   (Spain)

Author keywords

ADPKD; Antifibrinolytic; Cyst bleeding; Haematuria; Renal function; Tranexamic acid

Indexed keywords

ANTIFIBRINOLYTIC AGENT; TRANEXAMIC ACID;

ADULT; ARTICLE; FEMALE; HEMATURIA; HOSPITALIZATION; HUMAN; KIDNEY POLYCYSTIC DISEASE; MALE; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; ANTIFIBRINOLYTIC AGENTS; FEMALE; HEMATURIA; HUMANS; MALE; MIDDLE AGED; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TRANEXAMIC ACID; YOUNG ADULT;

EID: 84864404548     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2011.Dec.11210     Document Type: Article

References (39)

1. Gabow PA, Duley I, Johnson AM. Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease. Am J Kidney Dis 1992;20:140-3.
2. Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, et al. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 1992;41:1311-9.
3. Johnson AM, Gabow PA. Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J Am Soc Nephrol 1997;8:1560-67.
4. Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol 2006;1:148-57.
5. Masoumi A, Reed-Gitomer B, Kelleher C, Bekheirnia MR, Schrier RW. Developments in the management of autosomal dominant polycystic kidney disease. Ther Clin Risk Manag 2008;4:393-407.
6. Grantham JJ, Torres VE, Chapman AB, CRISP Investigators. Volume progression in polycystic kidney disease. N Engl J Med 2006;354:2122-30.
7. Ubara Y. New therapeutic option for autosomal dominant polycystic kidney disease patients with enlarged kidney and liver. Ther Apher Dial 2006;10:333-41.
8. Zwettler U, Zeier M, Andrassy K, Geberth S, Rambausek M. Treatment of gross hematuria in autosomal dominant polycystic kidney disease with aprotinin and desmopressin acetate. Nephron 1992;60:374.
9. Vujkovac B, Sabovic M. A successful treatment of life-threatening bleeding from polycystic kidneys with antifibrinolytic agent tranexamic acid. Blood Coagul Fibrinolysis 2006;17:589-91.
10. Alameel T, West M. Tranexamic acid treatment of life-threatening hematuria in polycystic kidney disease. Int J Nephrol 2011;203579. Epub 2011 Jun 1.
11. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999;57:1005-32.
12. Mannucci PM. Hemostatic drugs. N Engl J Med 1998;339:245-53.
13. Mezzano D, Panes O, Muñoz B, Pais E, Tagle R, González F, et al. Tranexamic acid inhibits fibrinolysis, shortens the bleeding time and improves platelet function in patients with chronic renal failure. Thromb Haemost 1999;82:1250-4.
14. Downey P, Tagle R, Pereira J, Mezzano D. Tranexamic acid and uremic bleeding: evidence-based treatment recommendations. Nat Clin Pract Nephrol 2007;3:E2.
15. Sabovic M, Zupan IP, Salobir B, Zupan I, Cernelc P, Lavre J, et al. The effect of long-term, low-dose tranexamic acid treatment on platelet dysfunction and haemoglobin levels in haemodialysis patients. Thromb Haemost 2005;94:1245-50.
16. Sabovic M, Lavre J, Vujkovac B. Tranexamic acid is beneficial as adjunctive therapy in treating major upper gastrointestinal bleeding in dialysis patients. Nephrol Dial Transplant 2003;18:1388-91.
17. Rannikko A, Petas A, Taari K. Tranexamic acid in control of primary hemorrhage during transurethral prostatectomy. Urology 2004;64:955-8.
18. Leslie CL, Simon BJ, Lee KF, Emhoff TA, Munshi IA. Bilateral rupture of multicystic kidneys after blunt abdominal trauma. J Trauma 2000;48:336-7.
19. Mufarrij AJ, Hitti E. Acute cystic rupture and hemorrhagic shock after a vigorous massage chair session in a patient with polycystic kidney disease. Am J Med Sci 2011;342:76-8.
20. Reay EK, McEleny K, McDonald S, Thorpe AC. Blunt renal trauma in adult polycystic kidney disease and the use of nephron sparing selective arterial embolization. J Trauma 2009;66:564-6.
21. Bajwa ZH, Gupta S, Warfield CA, Steinman TI. Pain management in polycystic kidney disease. Kidney Int 2001;60:1631-44.
22. Bajwa ZH, Sial KA, Malik AB, Steinman TI. Pain patterns in patients with polycystic kidney disease. Kidney Int 2004;66:1561-9.
23. Bello-Reuss E, Holubec K, Rajaraman S. Angiogenesis in autosomaldominant polycystic kidney disease. Kidney Int 2001;60:37-45.
24. Wei W, Popov V, Walocha JA, Wen J, Bello-Reuss E. Evidence of angiogenesis and microvascular regression in autosomal-dominant polycystic kidney disease kidneys: a corrosion cast study. Kidney Int 2006;70:1261-8.
25. Chen JH, Wu ST, Wu CC. Autosomal dominant polycystic kidney disease with cystic haemorrhage and infection. Acta Clin Belg 2010;65:446-7.
26. Piccoli GB, Arena V, Consiglio V, Deagostini MC, Pelosi E, Douroukas A, et al. Positron emission tomography in the diagnostic pathway for intracystic infection in ADPKD and "cystic" kidneys. A case series. BMC Nephrol 2011;12:48.
27. Jouret F, Lhommel R, Beguin C, Devuyst O, Pirson Y, Hassoun Z, et al. Positron-emission computed tomography in cyst infection diagnosis in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011;6:1644-50.
28. Levine E, Grantham JJ. High-density renal cysts in autosomal dominant polycystic kidney disease demonstrated by CT. Radiology 1985;154:477-82.
29. Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med 1993;329:332-42.
30. Davis NF, McGuire BB, Lawlor L, O'Gorman P, O'Malley KJ, Fitzpatrick JM. Oral tranexamic acid as a novel treatment option for persistent haematuria in patients with sickle cell disease. Ann Hematol 2010;89:1179-80.
31. Koo JR, Lee YK, Kim YS, Cho WY, Kim HK, Won NH. Acute renal cortical necrosis caused by an antifibrinolytic drug (tranexamicacid). Nephrol Dial Transplant 1999;14:750-2.
32. Odabas AR, Cetinkaya R, Selçuk Y, Kaya H, Coflkun U. Tranexamicacid- induced acute renal cortical necrosis in a patient with haemophilia A. Nephrol Dial Transplant 2001;16:189-90.
33. Hui AC, Wong TY, Chow KM, Szeto CC. Multifocal myoclonus secondary to tranexamic acid. J Neurol Neurosurg Psychiatry 2003;74:547.
34. Andersson L, Eriksson O, Hedlund PO, Kjellman H, Lindqvist B. Special considerations with regard to the dosage of tranexamic acid in patients with chronic renal diseases. Urol Research 1978;6:83-8.
35. Peces R, Peces C, Cuesta-López E, Vega-Cabrera C, Azorín S, Pérez- Dueñas V, et al. Co-inheritance of autosomal dominant polycystic kidney disease and sickle cell trait in African-americans. Nefrologia 2011;31:162-8.
36. Peces R, Peces C, Pérez-Dueñas V, Cuesta-López E, Azorín S, Selgas R. Rapamycin reduces kidney volume and delays the loss of renal function in a patient with autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant Plus 2009;2:133-5.
37. Peces R, Peces C, Cuesta-López E, Pérez-Dueñas V, Vega-Cabrera C, Azorín S, et al. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex. Nephrol Dial Transplant 2010;25:3787-91.
38. Reay EK, McEleny K, McDonald S, Thorpe AC. Blunt renal trauma in adult polycystic kidney disease and the use of nephron sparing selective arterial embolization. J Trauma 2009;66:564-6.
39. Bae KT, Grantham JJ. Imaging for the prognosis of autosomal dominant polycystic kidney disease. Nat Rev Nephrol 2010;6:96-106.